Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Sanara MedTech ( (SMTI) ) is now available.
On January 21, 2025, Sanara MedTech Inc. announced an exclusive licensing and distribution agreement with Biomimetic Innovations Ltd., acquiring U.S. marketing rights for OsStic® and related technologies, which address over 100,000 annual U.S. procedures. The agreement is complemented by Sanara’s €8.0 million investment in Biomimetic, granting them a 12.5% equity stake and board representation. This strategic move is expected to enhance Sanara’s surgical portfolio and market positioning, leveraging the FDA’s Breakthrough Device Designation for OsStic to introduce these innovative solutions to the U.S. market by early 2027.
More about Sanara MedTech
Sanara MedTech Inc., based in Fort Worth, Texas, is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound, and skincare markets. The company markets, distributes, and develops a range of surgical, wound, and skincare products primarily within the North American advanced wound care and surgical tissue repair markets.
YTD Price Performance: 2.72%
Average Trading Volume: 31,362
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $297.2M
For an in-depth examination of SMTI stock, go to TipRanks’ Stock Analysis page.
